NASDAQ:GRCE Grace Therapeutics (GRCE) Stock Price, News & Analysis $2.49 +0.11 (+4.62%) As of 04/25/2025 03:59 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsHeadlinesSEC FilingsTrendsBuy This Stock About Grace Therapeutics Stock (NASDAQ:GRCE) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Grace Therapeutics alerts:Sign Up Key Stats Today's Range$2.32▼$2.4950-Day Range$1.80▼$3.3952-Week Range$1.75▼$4.97Volume10,544 shsAverage Volume66,044 shsMarket Capitalization$25.25 millionP/E RatioN/ADividend YieldN/APrice Target$12.00Consensus RatingBuy Company OverviewGrace Therapeutics Inc. is a late-stage biopharma company advancing GTx-104, its novel injectable formulation of nimodipine which addresses high unmet medical needs for a rare disease, aneurysmal subarachnoid hemorrhage. Grace Therapeutics Inc., formerly known as Acasti Pharma Inc., is based in Princeton, New Jersey.Read More… Grace Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks47th Percentile Overall ScoreGRCE MarketRank™: Grace Therapeutics scored higher than 47% of companies evaluated by MarketBeat, and ranked 652nd out of 916 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingGrace Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageGrace Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Grace Therapeutics' stock forecast and price target. Earnings and Valuation1.3 / 5Proj. Earnings GrowthGrowing Earnings GrowthEarnings for Grace Therapeutics are expected to grow in the coming year, from ($1.06) to ($0.75) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Grace Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Grace Therapeutics is -2.15, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioGrace Therapeutics has a P/B Ratio of 0.48. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Grace Therapeutics' valuation and earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for GRCE. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldGrace Therapeutics does not currently pay a dividend.Dividend GrowthGrace Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Short InterestThere is no current short interest data available for GRCE. News and Social Media2.7 / 5News SentimentN/A News SentimentGrace Therapeutics has a news sentiment score of 1.91. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 1.03 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Grace Therapeutics this week, compared to 1 article on an average week. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Grace Therapeutics insiders have not sold or bought any company stock.Percentage Held by Insiders13.51% of the stock of Grace Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 6.08% of the stock of Grace Therapeutics is held by institutions.Read more about Grace Therapeutics' insider trading history. Receive GRCE Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Grace Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address GRCE Stock News HeadlinesGrace Therapeutics Announces Alignment with the FDA Supporting the Planned NDA Submission for GTx-104April 9, 2025 | globenewswire.comGrace Therapeutics files to sell 8.84M shares of common stock for holdersMarch 10, 2025 | markets.businessinsider.comM.A.G.A. is Finished – This Could be even BetterYou’ve no doubt heard Trump’s rally cry: Make America Great Again. But recently the President made a big change. Make America Wealthy Again (M.A.W.A).April 26, 2025 | Paradigm Press (Ad)Grace Therapeutics Files Form S-3 for Flexible Securities OfferingMarch 10, 2025 | tipranks.comGrace Therapeutics to Participate in the TD Cowen 45th Annual Health Care ConferenceFebruary 25, 2025 | globenewswire.comGRCE: STRIVE-ON Results ReportedFebruary 21, 2025 | finance.yahoo.comGrace Therapeutics Announces Third Fiscal Quarter 2025 Financial Results, Provides Business UpdateFebruary 13, 2025 | markets.businessinsider.comGrace Therapeutics reports Q3 EPS (36c), consensus (46c)February 13, 2025 | markets.businessinsider.comSee More Headlines GRCE Stock Analysis - Frequently Asked Questions How have GRCE shares performed this year? Grace Therapeutics' stock was trading at $3.74 at the beginning of 2025. Since then, GRCE stock has decreased by 33.4% and is now trading at $2.49. View the best growth stocks for 2025 here. How were Grace Therapeutics' earnings last quarter? Grace Therapeutics, Inc. (NASDAQ:GRCE) released its quarterly earnings results on Thursday, February, 13th. The company reported ($0.26) earnings per share for the quarter, topping analysts' consensus estimates of ($0.27) by $0.01. How do I buy shares of Grace Therapeutics? Shares of GRCE stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Company Calendar Last Earnings2/13/2025Today4/26/2025Next Earnings (Estimated)6/20/2025Fiscal Year End3/31/2026Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:GRCE Previous SymbolNASDAQ:GRCE CIK1444192 Webwww.acastipharma.com Phone818-839-4378Fax45-0687-2272EmployeesN/AYear FoundedN/APrice Target and Rating Average Stock Price Target$12.00 High Stock Price Target$12.00 Low Stock Price Target$12.00 Potential Upside/Downside+381.9%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($1.16) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-12,850,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-20.10% Return on Assets-17.10% Debt Debt-to-Equity RatioN/A Current Ratio6.06 Quick Ratio6.06 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$5.14 per share Price / Book0.48Miscellaneous Outstanding Shares10,140,000Free Float8,770,000Market Cap$25.25 million OptionableN/A Beta1.33 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report This page (NASDAQ:GRCE) was last updated on 4/26/2025 by MarketBeat.com Staff From Our PartnersClaim Your FREE Protection GuideIn the final days of his first term, Trump quietly left open an "off the books" wealth-protection loophole hid...American Alternative | SponsoredTrump’s tariffs just split the AI market in twoTrump’s tariff just split the AI market – among others – in two. One group of AI companies—the ones relying...Traders Agency | SponsoredURGENT: Someone's Moving Gold Out of London...People who don’t understand the gold market are about to lose a lot of money. Unfortunately, most so-called “g...Golden Portfolio | SponsoredJames Altucher: Do not invest in AI unless…I made millions during the crypto boom. Many “experts” are now saying… Artificial Intelligence opportuni...Paradigm Press | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowThe July 23rd Crypto Trigger Could Mark the Beginning of Bitcoin’s Next Big Move Bitcoin’s early 2024 ETF r...Crypto Swap Profits | SponsoredIt’s absolute chaos in Silicon Valley right now…If you missed out on the big boom in Nvidia… Listen up, because according to Nvidia's own CEO… Elon Musk...Brownstone Research | SponsoredSilicon Valley Gold RushA new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredTrump’s treachery Forget what the media tells you. Trump’s inner circle may be pushing a financial reset that mirrors moves from...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Grace Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Grace Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.